GlassScriptPhysician profile
Christian A Kcomt
NPI 1003918087
$10,981.02
in general payments reported to CMS, 2019-2025
24 companies · $2,301 in 2025
The $2,301 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $65.30 · 2021: $345 · 2022: $1,988 · 2023: $3,240 · 2024: $2,662 · 2025: $2,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,199 · Education: $4.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,198.92 |
| Education | $4.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,062.84 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,095.64 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $1,010.84 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $975.52 | 2020-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $952.59 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $913.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $676.13 | 2022-2025 | Lybalvi, Aristada |
| Lundbeck LLC | $640.29 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.96 | 2022-2025 | Caplyta |
| Corium, LLC | $528.16 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $308.86 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $249.27 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $206.07 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $204.32 | 2019-2024 | Ingrezza |
| Almatica Pharma LLC | $151.90 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $136.28 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $56.62 | 2019-2025 | Fanapt |
| Noven Therapeutics, LLC | $44.42 | 2024 | Xelstrym, Secuado |
| Allergan, INC. | $40.10 | 2019-2020 | |
| Shire North American Group INC | $36.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.13 | 2019 | |
| Owp Pharmaceuticals, INC. | $23.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.02 | 2024 | Austedo Xr |
| Neuronetics, INC. | $18.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Kcomt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.